Cargando…

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

OBJECTIVE: Human regular U-500 (U-500R) insulin (500 units/mL) is increasingly being used clinically, yet its pharmacokinetics (PK) and pharmacodynamics (PD) have not been well studied. Therefore, we compared PK and PD of clinically relevant doses of U-500R with the same doses of human regular U-100...

Descripción completa

Detalles Bibliográficos
Autores principales:	de la Peña, Amparo, Riddle, Matthew, Morrow, Linda A., Jiang, Honghua H., Linnebjerg, Helle, Scott, Adam, Win, Khin M., Hompesch, Marcus, Mace, Kenneth F., Jacobson, Jennie G., Jackson, Jeffrey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220843/ https://www.ncbi.nlm.nih.gov/pubmed/21994429 http://dx.doi.org/10.2337/dc11-0721

Ejemplares similares

Delayed Response to U-500 Regular Insulin
por: Davidson, Mayer B.
Publicado: (2018)

MON-152 Less Is More: Human Regular U-500 Insulin
por: Lugo Lopez, Zahira, et al.
Publicado: (2019)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

FRI654 Concentrated Regular U-500 Insulin In An Automated Insulin Delivery System: A Case Report
por: Aurora, John, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males
por: Hompesch, Marcus, et al.
Publicado: (2021)

U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients
por: Davidson, Mayer B., et al.
Publicado: (2010)

Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial
por: Kabul, Samaneh, et al.
Publicado: (2016)

Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center
por: Shaw, Kathy F., et al.
Publicado: (2017)

Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes
por: Shrestha, Rupendra T., et al.
Publicado: (2018)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
por: Grunberger, George, et al.
Publicado: (2020)

Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study
por: Eby, Elizabeth L, et al.
Publicado: (2015)

Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes
por: Chen, Jieling, et al.
Publicado: (2020)

Advancing Patient Safety and Access to Concentrated Insulin (U-500 Regular Insulin) in the Veterans Health Administration: A Clinician Education Program in the Primary Care Setting
por: Lutz-McCain, Stacey J., et al.
Publicado: (2018)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

SAT167 Risk Of Life Threatening Hypoglycemia When Using U-100 Insulin Syringes To Administer R U-500 Insulin
por: Rizwan, Tehlil, et al.
Publicado: (2023)

Erratum: Delayed Response to U-500 Regular Insulin. Clinical Diabetes 2018;36: 77–79 (DOI: 10.2337/cd16-0058)
por: Davidson, Mayer B.
Publicado: (2018)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Human Regular 500 units/mL Insulin Therapy: A Review of Clinical Evidence and New Delivery Options
por: Sze, David, et al.
Publicado: (2018)

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Prolonged hyperinsulinemia after subcutaneous injection of 2400 U regular insulin in a suicide attempt: Time course of serum insulin with frequent measurements
por: Hiromine, Yoshihisa, et al.
Publicado: (2012)

LBSUN294 Insulin-induced Abdominal Acanthosis Nigricans From High Doses Of Insulin U-500
por: Yap, Sara Elizabeth, et al.
Publicado: (2022)

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
por: Kapitza, Christoph, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2023)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus
por: Pettitt, D. J., et al.
Publicado: (2007)

Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes
por: Forst, Thomas, et al.
Publicado: (2010)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

U500 Disposable Patch Insulin Pump: Results and Discussion of a Veterans Affairs Pilot Study
por: Martin, Christopher, et al.
Publicado: (2018)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting
por: Dumont, Cyndi, et al.
Publicado: (2020)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015)

Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin
por: Chen, Jieling, et al.
Publicado: (2022)

Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience
por: Chawla, Manoj, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5f8pcecvr0hsc60kk9am4s9lq8